Literature DB >> 30753871

The KN-93 Molecule Inhibits Calcium/Calmodulin-Dependent Protein Kinase II (CaMKII) Activity by Binding to Ca2+/CaM.

Melanie H Wong1, Alexandra B Samal2, Mike Lee1, Jiri Vlach2, Nikolai Novikov1, Anita Niedziela-Majka1, Joy Y Feng1, Dmitry O Koltun1, Katherine M Brendza1, Hyock Joo Kwon1, Brian E Schultz1, Roman Sakowicz1, Jamil S Saad3, Giuseppe A Papalia4.   

Abstract

Calcium/calmodulin-dependent protein kinase II (CaMKII) is a multifunctional serine/threonine protein kinase that transmits calcium signals in various cellular processes. CaMKII is activated by calcium-bound calmodulin (Ca2+/CaM) through a direct binding mechanism involving a regulatory C-terminal α-helix in CaMKII. The Ca2+/CaM binding triggers transphosphorylation of critical threonine residues proximal to the CaM-binding site leading to the autoactivated state of CaMKII. The demonstration of its critical roles in pathophysiological processes has elevated CaMKII to a key target in the management of numerous diseases. The molecule KN-93 is the most widely used inhibitor for studying the cellular and in vivo functions of CaMKII. It is widely believed that KN-93 binds directly to CaMKII, thus preventing kinase activation by competing with Ca2+/CaM. Herein, we employed surface plasmon resonance, NMR, and isothermal titration calorimetry to characterize this presumed interaction. Our results revealed that KN-93 binds directly to Ca2+/CaM and not to CaMKII. This binding would disrupt the ability of Ca2+/CaM to interact with CaMKII, effectively inhibiting CaMKII activation. Our findings also indicated that KN-93 can specifically compete with a CaMKIIδ-derived peptide for binding to Ca2+/CaM. As indicated by the surface plasmon resonance and isothermal titration calorimetry data, apparently at least two KN-93 molecules can bind to Ca2+/CaM. Our findings provide new insight into how in vitro and in vivo data obtained with KN-93 should be interpreted. They further suggest that other Ca2+/CaM-dependent, non-CaMKII activities should be considered in KN-93-based mechanism-of-action studies and drug discovery efforts.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CaMKII; KN-92; KN-93; calmidazolium; calmodulin

Year:  2019        PMID: 30753871     DOI: 10.1016/j.jmb.2019.02.001

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  24 in total

1.  FRET-based sensor for CaMKII activity (FRESCA): A useful tool for assessing CaMKII activity in response to Ca2+ oscillations in live cells.

Authors:  Goli Ardestani; Megan C West; Thomas J Maresca; Rafael A Fissore; Margaret M Stratton
Journal:  J Biol Chem       Date:  2019-06-14       Impact factor: 5.157

2.  The CaMKII inhibitor KN93-calmodulin interaction and implications for calmodulin tuning of NaV1.5 and RyR2 function.

Authors:  Christopher N Johnson; Rekha Pattanayek; Franck Potet; Robyn T Rebbeck; Daniel J Blackwell; Roman Nikolaienko; Vasco Sequeira; Remy Le Meur; Przemysław B Radwański; Jonathan P Davis; Aleksey V Zima; Razvan L Cornea; Steven M Damo; Sandor Györke; Alfred L George; Björn C Knollmann
Journal:  Cell Calcium       Date:  2019-07-30       Impact factor: 6.817

3.  Calmodulin kinase 2 genetically interacts with Rch1p to negatively regulate calcium import into Saccharomyces cerevisiae after extracellular calcium pulse.

Authors:  Christian E Coleman; Chelsea Landin; Abigail Neuer; Fadi M Sayegh; Pamela A Marshall
Journal:  Arch Microbiol       Date:  2022-07-24       Impact factor: 2.667

4.  Involvement of calmodulin-dependent protein kinase I in the regulation of the expression of connexin 43 in MA-10 tumor Leydig cells.

Authors:  Mustapha Najih; Ha Tuyen Nguyen; Luc J Martin
Journal:  Mol Cell Biochem       Date:  2022-09-12       Impact factor: 3.842

Review 5.  Inhibitors of Mitochondrial Dynamics Mediated by Dynamin-Related Protein 1 in Pulmonary Arterial Hypertension.

Authors:  Fan Xiao; Rui Zhang; Lan Wang
Journal:  Front Cell Dev Biol       Date:  2022-06-30

6.  CaMKII binding to GluN2B at S1303 has no role in acute or inflammatory pain.

Authors:  Uche P Maduka; Stephanie R White; Mei-Ling A Joiner; Johannes W Hell; Donna L Hammond
Journal:  Brain Res       Date:  2020-10-14       Impact factor: 3.252

7.  Convergent NMDA receptor-Pannexin1 signaling pathways regulate the interaction of CaMKII with Connexin-36.

Authors:  Ryan C F Siu; Anna Kotova; Ksenia Timonina; Christiane Zoidl; Georg R Zoidl
Journal:  Commun Biol       Date:  2021-06-08

8.  TRPV4 disrupts mitochondrial transport and causes axonal degeneration via a CaMKII-dependent elevation of intracellular Ca2.

Authors:  Brian M Woolums; Brett A McCray; Hyun Sung; Masashi Tabuchi; Jeremy M Sullivan; Kendra Takle Ruppell; Yunpeng Yang; Catherine Mamah; William H Aisenberg; Pamela C Saavedra-Rivera; Bryan S Larin; Alexander R Lau; Douglas N Robinson; Yang Xiang; Mark N Wu; Charlotte J Sumner; Thomas E Lloyd
Journal:  Nat Commun       Date:  2020-05-29       Impact factor: 14.919

9.  Antagonism of the mu-delta opioid receptor heterodimer enhances opioid antinociception by activating Src and calcium/calmodulin-dependent protein kinase II signaling.

Authors:  Attila Keresztes; Keith Olson; Paul Nguyen; Marissa A Lopez-Pier; Ryan Hecksel; Natalie K Barker; Zekun Liu; Victor Hruby; John Konhilas; Paul R Langlais; John M Streicher
Journal:  Pain       Date:  2022-01-01       Impact factor: 6.961

10.  MICAL1 constrains cardiac stress responses and protects against disease by oxidizing CaMKII.

Authors:  Klitos Konstantinidis; Vassilios J Bezzerides; Lo Lai; Holly M Isbell; An-Chi Wei; Yuejin Wu; Meera C Viswanathan; Ian D Blum; Jonathan M Granger; Danielle Heims-Waldron; Donghui Zhang; Elizabeth D Luczak; Kevin R Murphy; Fujian Lu; Daniel H Gratz; Bruno Manta; Qiang Wang; Qinchuan Wang; Alex L Kolodkin; Vadim N Gladyshev; Thomas J Hund; William T Pu; Mark N Wu; Anthony Cammarato; Mario A Bianchet; Madeline A Shea; Rodney L Levine; Mark E Anderson
Journal:  J Clin Invest       Date:  2020-09-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.